Eugene Schneider
Ionis Pharmaceuticals (United States)(US)
Publications by Year
Research Areas
Neurogenetic and Muscular Disorders Research, Amyloidosis: Diagnosis, Treatment, Outcomes, Coagulation, Bradykinin, Polyphosphates, and Angioedema, RNA modifications and cancer, Lysosomal Storage Disorders Research
Most-Cited Works
- → Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy(2017)2,217 cited
- → Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy(2018)1,401 cited
- → Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study(2016)1,008 cited
- → Nusinersen in later-onset spinal muscular atrophy(2019)258 cited
- → Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment(2006)223 cited
- → Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy(2023)176 cited
- → Clinical Effect And Safety Profile of Recombinant Human Lysosomal Acid Lipase in Patients With Cholesteryl Ester Storage Disease(2013)117 cited
- → Rapid progression and mortality of lysosomal acid lipase deficiency presenting in infants(2015)116 cited
- → Treatment of infantile-onset spinal muscular atrophy with nusinersen: final report of a phase 2, open-label, multicentre, dose-escalation study(2021)101 cited
- → Sebelipase alfa over 52weeks reduces serum transaminases, liver volume and improves serum lipids in patients with lysosomal acid lipase deficiency(2014)96 cited